Clinical Trials Logo

Filter by:
NCT ID: NCT00647192 Terminated - Atrial Fibrillation Clinical Trials

EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

EPLERAF
Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Eplerenone reduces atrial fibrillation (AF) recurrences within the first 8 weeks after electrical cardioversion of persistent AF.

NCT ID: NCT00643591 Terminated - Clinical trials for Cerebral Astrocytoma, High Grade

Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma

Start date: June 2008
Phase: N/A
Study type: Observational

The objectives of the trial are: - To determine the localisation within the primary tumor of the therapy resistant cells, before and during radiotherapy to determine a possible accurate boost volume. - To determine changes during treatment intra- and extratumoral within the irradiated area.(Intratumoral: change of up-take - decrease, increase, change of localization/ Extratumoral: effects of temporal changes in up-take - e.g. due to oedema).

NCT ID: NCT00642941 Terminated - Sarcoma Clinical Trials

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Start date: December 18, 2007
Phase: Phase 2
Study type: Interventional

The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.

NCT ID: NCT00642902 Terminated - Clinical trials for Relapsing Multiple Sclerosis

Atacicept in Multiple Sclerosis, Phase II

Start date: March 2008
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces Central Nervous System inflammation in subjects with RMS as assessed by frequent MRI. This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.

NCT ID: NCT00642083 Terminated - Outflow Stenosis Clinical Trials

Stenting of Haemodialysis Acces Trial

SHARE
Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of a PTFE covered stent-graft in the prevention of outflow re-stenosis in loop fistula in a prospective trial.

NCT ID: NCT00640016 Terminated - Asthma Clinical Trials

A Study to Assess the Efficacy, Safety,and Tolerability of CAT-354

Start date: March 2008
Phase: Phase 2
Study type: Interventional

To investigate the effects of CAT-354 on airway hyperresponsiveness (AHR) in uncontrolled asthma.

NCT ID: NCT00637624 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

NAC-PNP
Start date: March 2008
Phase: N/A
Study type: Interventional

In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing cisplatin.

NCT ID: NCT00634933 Terminated - Clinical trials for Arthritis, Rheumatoid

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Start date: March 2008
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.

NCT ID: NCT00631267 Terminated - Colles' Fracture Clinical Trials

CoNCReTe-trial: Colles Fractures, Determining the Norm in Closed Reduction Techniques

CoNCReTe
Start date: July 2008
Phase: N/A
Study type: Interventional

Rationale: Many different closed techniques are used to reduce a dorsally dislocated distal radius fracture (Colles' fracture). One trial to compare two main techniques (finger-trap traction and manual manipulation) did not find significant difference in radiological and clinical outcome (Earnshaw 2002). This trial aims to investigate patient and medical satisfaction between both techniques Objective: To demonstrate patient satisfaction (pain, duration, general) and medical satisfaction (difficulty of reposition). It is suggested that finger-trap traction causes less pain for patients and is more easy than manual manipulation but have the same radiological and clinical outcome. Study design: Randomised controlled intervention study Study population: 300 Patients with newly diagnosed closed distal radius fractures with dorsal angulation (Colles' fracture) older than 16years coming to the Emergency Medical Department. Intervention: One group is put in finger-trap traction (digitus 1-3) for 10minutes with 4-5kg of ballast on their upper arm followed by reduction by dorsal pressure. The other group is manually reduced according to Charnley with traction and "hooking over" of the fracture elements. Main study parameters/endpoints: Visual analogue scale of patient and medical satisfaction, percentage of successful primary reductions. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Apart for the regular follow-up of patients with distal radius fractures,one extra out-patient visit is necessary to assess functional outcome after three months.Finger-trap traction has a (theoretical) risk of causing traumatic damage to ligaments of the fingers, but this risk is in our opinion not higher than in the manual manipulation. It is expected that the finger-trap traction group is more satisfied because this technique seems less traumatic than but as successful as the manual manipulation group.

NCT ID: NCT00626548 Terminated - Prostate Cancer Clinical Trials

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

ENTHUSE M0
Start date: January 2008
Phase: Phase 3
Study type: Interventional

Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC). This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve progression-free survival and overall survival against a background of existing prostate cancer treatments. ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC) patients who have had rising PSA after surgical or medical castration but have no evidence of metastases. All patients participating in this clinical trial will receive existing prostate cancer treatments in addition to trial therapy. Half the patients will receive ZD4054 (Zibotentan) , and half the patients will receive placebo in addition to standard prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may slow the progression of the tumour. No patients will be deprived of standard prostate cancer therapy.